Abstract: Provided are methods for prophylaxis and therapy for viral infections. The methods can facilitate a synergistic anti-viral effect. The method involves administering a combination of agents to an individual in need thereof. The combinations of agents are selected from interferons (IFNs), Toll-Like Receptor (TLR) ligands, polyinosinic:polycytidylic acid, rintatolimod, tumor necrosis factor alpha (TNF-a) or an inducer thereof, and nuclear factor kappa B (NF-xB) or an inducer or activator thereof.

Abstract: Provided herein are active CXCR4+ CD8; T cells, active CXCR4+ type-1 CD4+ T cells and active CXCR4+ NK cells and populations of those cells, methods for making active CXCR4+ T cells and NK cells and populations of those cells, and methods for using active CXCR4+ T cells and NK cells and populations of those cells for the treatment of cancer, precartcerous conditions and chronic infections.

Abstract: Provided herein are active CXCR4+ CD8+ T cells, active CXCR4+ type-1 CD4+ T cells and active CXCR4+ NK cells and populations of those cells, methods for making active CXCR4+ T cells and NK cells and populations of those cells, and methods for using active CXCR4+ T cells and NK cells and populations of those cells for the treatment of cancer, precancerous conditions and chronic infections.

Abstract: Provided herein are ST-?DC1 and populations of those cells, methods for making ST-?DC1 and populations of those cells, and methods for using ST-?DC1 and populations of those cells for the treatment of cancer, precancerous conditions and chronic infections.

Abstract: Provided herein are active CXCR4+ CD8+ T cells, active CXCR4+ type-1 CD4+ T cells and active CXCR4+ NK cells and populations of those cells, methods for making active CXCR4+ T cells and NK cells and populations of those cells, and methods for using active CXCR4+ T cells and NK cells and populations of those cells for the treatment of cancer, precancerous conditions and chronic infections.

Abstract: Therapies effective for the treatment and prevention of cancer and other diseases are disclosed. These methods include the administration of therapeutically effective amounts of agents that increase the local production of effector cell-attracting chemokines within tumor lesions, with concomitant suppression of local production of undesirable chemokines that attract regulatory T(reg) cells. These methods include administering to the subject therapeutically effective amounts of a Toll-like receptor (TLR) agonist or other activator of NF-KB pathway in combination with a blocker of prostaglandin synthesis or a blocker of prostaglandin signaling, in combination with a type-1 interferon, or in combination with both a blocker of prostaglandin synthesis or signaling and with a type-1 interferon.

Abstract: Therapies effective for the treatment and prevention of autoimmune diseases, chronic inflammatory diseases, transplant rejection or Graft versus Host Disease (GvH), using prostaglandin (PG), alternative agonists of PG receptors, EP2 or EP4, or other activators of adenylate cyclase/cAMP/PKA/CREB signaling pathway are disclosed herein. These methods include the administration of a therapeutically effective amount of myeloid cells pre-treated ex vivo with the above-mentioned factors, or the in vivo administration of such agents in combination with the factors attracting myeloid precursor cells, such as myeloid cell-attracting chemokines or their inducers. Such therapies can be applied for the prevention or treatment of autoimmune diseases, spontaneous and specific pathogen-induced inflammatory diseases (including some infectious diseases), premalignant and malignant lesions, and for prevention and treatment of transplant rejection and GvH.

Abstract: The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFN? and other ligands of the IFN? receptor, in combination with IFN? (or other type I interferons), poly I:C, and other IFN? (and IFN?) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium.

Abstract: The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFN? and other ligands of the IFN? receptor, in combination with IFN? (or other type I interferons), poly I:C, and other IFN? (and IFN?) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium.

Abstract: The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFN? and other ligands of the IFN? receptor, in combination with IFN? (or other type I interferons), poly I:C, and other IFN? (and IFN?) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium.

Abstract: The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFN? and other ligands of the IFN? receptor, in combination with IFN? (or other type I interferons), poly I:C, and other IFN? (and IFN?) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium.

Abstract: The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFN? and other ligands of the IFN?receptor, in combination with IFN? (or other type I interferons), poly I:C, and other IFN? (and IFN?) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70 allows for the generation of fully-mature DC1s in serum-free AIM-V medium.

Abstract: The invention provides compositions and methods for treating or preventing a target disease in a mammal by induction of memory T cells. The methods comprise (1) administering a sensitizing composition comprising a non-target antigen to a patient; and (2) administering a therapeutic composition comprising a non-target antigen and a target antigen to the patient, wherein the target antigen is associated with the disease, and wherein the therapeutic composition is administered after the sensitizing compositions, at an interval sufficient for induction of memory T cells. The methods can alternatively comprise administering a target antigen along with an inhibitory agent such as an inhibitor of DC apoptosis, an inhibitor of Granzyme B, a Granzyme-B-inducible mediator of apoptosis, an inhibitor of perforin, or a perforin-inducible mediator of apoptosis.

Abstract: The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFN? and other ligands of the IFN? receptor, in combination with IFN? (or other type I interferons), poly I:C, and other IFN? (and IFN?) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium.

Abstract: The invention provides compositions and methods for treating or preventing a target disease in a mammal by induction of memory T cells. The methods comprise (1) administering a sensitizing composition comprising a non-target antigen to a patient; and (2) administering a therapeutic composition comprising a non-target antigen and a target antigen to the patient, wherein the target antigen is associated with the disease, and wherein the therapeutic composition is administered after the sensitizing compositions, at an interval sufficient for induction of memory T cells. The methods can alternatively comprise administering a target antigen along with an inhibitory agent such as an inhibitor of DC apoptosis, an inhibitor of granzyme B, a Granzyme-B-inducible mediator of apoptosis, an inhibitor of perforin, or a perforin-inducible mediator of apoptosis.

Abstract: The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFN? and other ligands of the IFN? receptor, in combination with IFN? (or other type I interferons), poly I:C, and other IFN? (and IFN?) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium.